Literature DB >> 23841730

U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination.

Marie R Griffin1, Yuwei Zhu, Matthew R Moore, Cynthia G Whitney, Carlos G Grijalva.   

Abstract

BACKGROUND: The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into the U.S. childhood immunization schedule in 2000 has substantially reduced the incidence of vaccine-serotype invasive pneumococcal disease in young children and in unvaccinated older children and adults. By 2004, hospitalizations associated with pneumonia from any cause had also declined markedly among young children. Because of concerns about increases in disease caused by nonvaccine serotypes, we wanted to determine whether the reduction in pneumonia-related hospitalizations among young children had been sustained through 2009 and whether such hospitalizations in older age groups had also declined.
METHODS: We estimated annual rates of hospitalization for pneumonia from any cause using the Nationwide Inpatient Sample database. The reason for hospitalization was classified as pneumonia if pneumonia was the first listed diagnosis or if it was listed after a first diagnosis of sepsis, meningitis, or empyema. Average annual rates of pneumonia-related hospitalizations from 1997 through 1999 (before the introduction of PCV7) and from 2007 through 2009 (well after its introduction) were used to estimate annual declines in hospitalizations due to pneumonia.
RESULTS: The annual rate of hospitalization for pneumonia among children younger than 2 years of age declined by 551.1 per 100,000 children (95% confidence interval [CI], 445.1 to 657.1), which translates to 47,000 fewer hospitalizations annually than expected on the basis of the rates before PCV7 was introduced. The rate for adults 85 years of age or older declined by 1300.8 per 100,000 (95% CI, 984.0 to 1617.6), which translates to 73,000 fewer hospitalizations annually. For the three age groups of 18 to 39 years, 65 to 74 years, and 75 to 84 years, the annual rate of hospitalization for pneumonia declined by 8.4 per 100,000 (95% CI, 0.6 to 16.2), 85.3 per 100,000 (95% CI, 7.0 to 163.6), and 359.8 per 100,000 (95% CI, 199.6 to 520.0), respectively. Overall, we estimated an age-adjusted annual reduction of 54.8 per 100,000 (95% CI, 41.0 to 68.5), or 168,000 fewer hospitalizations for pneumonia annually.
CONCLUSIONS: Declines in hospitalizations for childhood pneumonia were sustained during the decade after the introduction of PCV7. Substantial reductions in hospitalizations for pneumonia among adults were also observed. (Funded by the Centers for Disease Control and Prevention.).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23841730      PMCID: PMC4877190          DOI: 10.1056/NEJMoa1209165

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  35 in total

Review 1.  Serotype replacement in disease after pneumococcal vaccination.

Authors:  Daniel M Weinberger; Richard Malley; Marc Lipsitch
Journal:  Lancet       Date:  2011-04-12       Impact factor: 79.321

Review 2.  Diagnostic tests for agents of community-acquired pneumonia.

Authors:  John G Bartlett
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

3.  Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization.

Authors:  Adam L Cohen; Lee H Harrison; Monica M Farley; Arthur L Reingold; James Hadler; William Schaffner; Ruth Lynfield; Ann R Thomas; Michael Campsmith; Jianmin Li; Anne Schuchat; Matthew R Moore
Journal:  AIDS       Date:  2010-09-10       Impact factor: 4.177

Review 4.  Nasopharyngeal colonization: a target for pneumococcal vaccination.

Authors:  Helena Käyhty; Kari Auranen; Hanna Nohynek; Ron Dagan; Helena Mäkelä
Journal:  Expert Rev Vaccines       Date:  2006-10       Impact factor: 5.217

5.  Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia.

Authors:  Andrew Jardine; Robert I Menzies; Peter B McIntyre
Journal:  Pediatr Infect Dis J       Date:  2010-07       Impact factor: 2.129

6.  Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States.

Authors:  Jennifer B Rosen; Ann R Thomas; Catherine A Lexau; Art Reingold; Jim L Hadler; Lee H Harrison; Nancy M Bennett; William Schaffner; Monica M Farley; Bernard W Beall; Matt R Moore
Journal:  Clin Infect Dis       Date:  2011-07-15       Impact factor: 9.079

7.  Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine--United States, 1997-2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-01-16       Impact factor: 17.586

8.  Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.

Authors:  Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson
Journal:  JAMA       Date:  2007-04-25       Impact factor: 56.272

9.  Population-based impact of pneumococcal conjugate vaccine in young children.

Authors:  Katherine A Poehling; Bonnie J Lafleur; Peter G Szilagyi; Kathryn M Edwards; Ed Mitchel; Richard Barth; Benjamin Schwartz; Marie R Griffin
Journal:  Pediatrics       Date:  2004-09       Impact factor: 7.124

10.  Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis.

Authors:  Carlos G Grijalva; J Pekka Nuorti; Patrick G Arbogast; Stacey W Martin; Kathryn M Edwards; Marie R Griffin
Journal:  Lancet       Date:  2007-04-07       Impact factor: 79.321

View more
  176 in total

1.  What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?

Authors:  A T Newall
Journal:  Hum Vaccin Immunother       Date:  2016-07-11       Impact factor: 3.452

2.  Impact of Infectious Diseases Society of America/Pediatric Infectious Diseases Society guidelines on treatment of community-acquired pneumonia in hospitalized children.

Authors:  Rachael K Ross; Adam L Hersh; Matthew P Kronman; Jason G Newland; Talene A Metjian; A Russell Localio; Theoklis E Zaoutis; Jeffrey S Gerber
Journal:  Clin Infect Dis       Date:  2014-01-06       Impact factor: 9.079

3.  Risk of hospitalization due to pneumococcal disease in adults in Spain. The CORIENNE study.

Authors:  Ruth Gil-Prieto; Raquel Pascual-Garcia; Stefan Walter; Alejandro Álvaro-Meca; Ángel Gil-De-Miguel
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

4.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Authors:  Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-07-14       Impact factor: 91.245

5.  Antibiotic Prescribing for Adults Hospitalized in the Etiology of Pneumonia in the Community Study.

Authors:  Sara Tomczyk; Seema Jain; Anna M Bramley; Wesley H Self; Evan J Anderson; Chris Trabue; D Mark Courtney; Carlos G Grijalva; Grant W Waterer; Kathryn M Edwards; Richard G Wunderink; Lauri A Hicks
Journal:  Open Forum Infect Dis       Date:  2017-06-20       Impact factor: 3.835

6.  Invasive pneumococcal disease in children can reveal a primary immunodeficiency.

Authors:  Jean Gaschignard; Corinne Levy; Maya Chrabieh; Bertrand Boisson; Cécile Bost-Bru; Stéphane Dauger; François Dubos; Philippe Durand; Joël Gaudelus; Dominique Gendrel; Christèle Gras Le Guen; Emmanuel Grimprel; Gaël Guyon; Catherine Jeudy; Eric Jeziorski; Francis Leclerc; Pierre-Louis Léger; Fabrice Lesage; Mathie Lorrot; Isabelle Pellier; Didier Pinquier; Loïc de Pontual; Philippe Sachs; Caroline Thomas; Pierre Tissières; Frédéric V Valla; Philippe Desprez; Véronique Frémeaux-Bacchi; Emmanuelle Varon; Xavier Bossuyt; Robert Cohen; Laurent Abel; Jean-Laurent Casanova; Anne Puel; Capucine Picard
Journal:  Clin Infect Dis       Date:  2014-04-23       Impact factor: 9.079

7.  Decrease in antibiotic use, an added benefit of PCVs.

Authors:  Carlos G Grijalva
Journal:  Lancet Infect Dis       Date:  2013-11-26       Impact factor: 25.071

8.  Incidence of Hospitalization for Vaccine-Preventable Infections in Children Following Solid Organ Transplant and Associated Morbidity, Mortality, and Costs.

Authors:  Amy G Feldman; Brenda L Beaty; Donna Curtis; Elizabeth Juarez-Colunga; Allison Kempe
Journal:  JAMA Pediatr       Date:  2019-03-01       Impact factor: 16.193

9.  Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly.

Authors:  Paolo Durando; Roberto Rosselli; Ilaria Cremonesi; Andrea Orsi; Erika Albanese; Ilaria Barberis; Chiara Paganino; Cecilia Trucchi; Mariano Martini; Lorenzo Marensi; Valter Turello; The Ligurian Pneumococcal Study Group; Alessandro Bregante; Roberto Cacciani; Rocco Iudici; Diego La Marca; Leonardo Pedano; Amadio Franco Petrucci; Maria Santolini; Valentina Sbisà; Monica Zacconi
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 10.  Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine.

Authors:  Inci Yildirim; Kimberly M Shea; Stephen I Pelton
Journal:  Infect Dis Clin North Am       Date:  2015-12       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.